JPMorgan analyst Jackson Ader kept his Neutral rating and $70 price target on Amdocs after its Analyst Day, saying the company's forecasts were "an excellent reminder of the consistency in execution" of its strategy. The analyst states that Amdocs' margins and 3-year forecasts for organic revenue growth of 2%-6% were in line with expectations, but he also believes that "there are enough growth drivers in the business to produce numbers ahead of the mid-point." Ader further cites the company's lack of exposure to the slowdown in China, the potential of its "direct to consumer" move in media, and the return from its 5G investment.